Shares of Exact Sciences Co. (NASDAQ:EXAS) have been assigned an average “Buy” rating by the fourteen research firms that cover the company, Marketbeat.com reports. One investment analyst gave the stock a sell rating, one gave the company a hold rating and eleven gave the company a buy rating. The 12-month average price target among brokerages that have reported on the stock over the past year is $134.23.
A number of stock analysts have weighed in on EXAS shares recently. SVB Leerink lowered its price target on Exact Sciences shares from $160.00 to $140.00 and set an “outperform” rating on the stock in a Wednesday, Nov. 3 research note. Cowen cut his price target on Exact Sciences shares from $160.00 to $135.00 and set an “outperform” rating on the stock in a Thursday, Oct. 14 research report. Wells Fargo & Company cut its price target on Exact Sciences stock from $120.00 to $95.00 and set an “equal weight” rating on the stock in a Wednesday, Nov. 3 research report . Robert W. Baird cut his price target on Exact Sciences stock from $125.00 to $116.00 and set an “outperform” rating on the stock in a Wednesday, Nov. 3 research report. Finally, Craig Hallum cut his price target on Exact Sciences shares from $144.00 to $133.00 and placed a “buy” rating on the stock in a Wednesday, Nov. 3 research report.
In other news from Exact Sciences, CEO Kevin T. Conroy sold 16,922 shares of the company in a trade dated Monday, Nov. 1. The shares were sold at an average price of $93.88, for a total value of $1,588,637.36. The transaction was disclosed in a document filed with the SEC, which can be accessed on the SEC’s website. 1.40% of the shares are currently held by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in shares of Exact Sciences by 8.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 19,789,343 shares of the medical research company valued at $2,460,013,000 after acquiring an additional 1,495,404 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Exact Sciences by 2.0% during the second quarter. Vanguard Group Inc. now owns 15,410,555 shares of the medical research company valued at $1,915,686,000 after acquiring 307,132 additional shares in the last quarter. Capital World Investors increased its stake in Exact Sciences shares by 6.9% during the 3rd quarter. Capital World Investors now owns 5,969,312 shares of the medical research company valued at $569,771,000 after acquiring 383,649 additional shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Exact Sciences by 25.0% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,679,730 shares of the medical research company valued at $446,680,000 after acquiring an additional 936,245 shares in the last quarter. Finally, Baillie Gifford & Co. increased its stake in Exact Sciences by 2.1% during the 4th quarter. Baillie Gifford & Co. now owns 4,543,994 shares of the medical research company valued at $353,658,000 after acquiring 91,467 additional shares in the last quarter. 90.22% of the shares are held by institutional investors.
Shares of NASDAQ EXAS were down $2.00 during Friday trading hours, hitting $74.03. 3,030,169 shares were traded, against an average volume of 2,639,333. The company has a quick ratio of 2.14, a current ratio of 2.27 and a leverage ratio of 0.55. Exact Sciences has a 12-month low of $69.75 and a 12-month high of $159.54. The company has a market capitalization of $12.76 billion, a PE ratio of -14.90 and a beta of 1.22. The company has a fifty-day moving average price of $80.15 and a 200-day moving average price of $94.15.
Exact Sciences Inc (NASDAQ:EXAS) last released its quarterly results on Monday, November 1. The medical research company reported ($0.97) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.89) by ($0.08). Exact Sciences had a negative return on equity of 11.53% and a negative net margin of 46.14%. The company posted revenue of $456.38 million for the quarter, versus analyst estimates of $429.04 million. During the same period last year, the company made ($0.36) earnings per share. As a group, stock analysts expect Exact Sciences to post earnings per share of -3.13 for the current fiscal year.
About the exact sciences
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. She developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is based in Madison, WI.
Feature article: What is a derivative?
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in the exact sciences right now?
Before you consider the exact sciences, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Exact Sciences wasn’t on the list.
While Exact Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here